I think anything is possible this year, with so many up and coming events one has to wonder what is the risk ratio of buying and holding against selling and missing out.
Within the next 3 months we have to my knowledge and understanding the most important news for the company there is apart from commercialisation.
1. Nasdaq listing which is a very short term announcement
2. New funding arrangement or some sort of investor (has to be short term announcement also)
3. The most importantly trial results
I think 40 cents is a walk in the park with just the nasdaq, that is my optimistic view after removal of ST, as i have come to ease with the company.
If you seen a 25% increase in SP for just the removal of ST and them buying in on their own will. Then one can only imagine what will happen, if there is a new funder on board with a much better option than we had before.
I think this is where the target was set for 63 cents. With both these announcement providing positive outcomes i think that price target is within reach.
Now the big game changer is the trial results. This can make or break us. With the results so far i think it can make us. Ultimately anything is possible i pray for the best as it will ultimately change the view of PRR for ever and hold these rampers in silence.
If these results come out with a better overall result than DNDN then i see $$$$ everywhere. Where to if results return positive? only market and experts valuing the company know better, only comparison is dndn.
I think then PRR would be more of a takeover target as it would be considered a very low risk for any company to take it to the end.
For the time being the wait continues and the strategists are playing there game.
- Forums
- ASX - By Stock
- IMM
- last chance
last chance , page-5
-
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
(20min delay)
|
|||||
Last
32.3¢ |
Change
-0.033(9.15%) |
Mkt cap ! $475.7M |
Open | High | Low | Value | Volume |
34.0¢ | 34.5¢ | 31.5¢ | $2.057M | 6.255M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
45 | 336972 | 32.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
32.5¢ | 168730 | 17 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
44 | 335490 | 0.320 |
25 | 502488 | 0.315 |
11 | 216798 | 0.310 |
13 | 165773 | 0.305 |
19 | 466218 | 0.300 |
Price($) | Vol. | No. |
---|---|---|
0.325 | 174974 | 18 |
0.330 | 366946 | 7 |
0.335 | 74357 | 6 |
0.340 | 451415 | 8 |
0.345 | 100299 | 6 |
Last trade - 15.20pm 15/07/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online